Related Experiment Videos
[Sulfalene circulation in kidney disease patients]
Antibiotiki
|March 1, 1981
Summary
Patients with chronic nephritis and kidney amyloidosis excrete sulfalen faster due to increased urinary drug excretion. This indicates altered sulfalen elimination in these kidney diseases.
Area of Science:
- Nephrology
- Pharmacokinetics
Background:
- Chronic nephritis and kidney amyloidosis are significant kidney diseases.
- Understanding drug metabolism and excretion in renal impairment is crucial for patient management.
Purpose of the Study:
- To investigate the excretion rate of sulfalen in patients with chronic nephritis and kidney amyloidosis.
- To compare sulfalen elimination in patients with kidney disease to healthy individuals.
Main Methods:
- Patient cohort included individuals with chronic nephritis and kidney amyloidosis.
- Control group comprised healthy individuals with normal kidney function.
- Sulfalen excretion and plasma clearance were measured.
Main Results:
- Patients with kidney diseases showed a higher rate of sulfalen excretion compared to the control group.
- Elevated sulfalen elimination rate and plasma clearance were observed in patients.
- Increased excretion of unchanged sulfalen in urine was identified as the cause.
Conclusions:
- Sulfalen is eliminated at a higher rate in patients suffering from chronic nephritis and kidney amyloidosis.
- Renal function alterations in these conditions affect sulfalen pharmacokinetics.
- Further research may be needed to adjust sulfalen dosage in patients with these kidney diseases.